153 related articles for article (PubMed ID: 23169782)
1. Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia.
Gruber M; Bellemare J; Hoermann G; Gleiss A; Porpaczy E; Bilban M; Le T; Zehetmayer S; Mannhalter C; Gaiger A; Shehata M; Fleiss K; Skrabs C; Lévesque É; Vanura K; Guillemette C; Jaeger U
Blood; 2013 Feb; 121(7):1175-83. PubMed ID: 23169782
[TBL] [Abstract][Full Text] [Related]
2. UGT2B17 modifies drug response in chronic lymphocytic leukaemia.
Allain EP; Rouleau M; Vanura K; Tremblay S; Vaillancourt J; Bat V; Caron P; Villeneuve L; Labriet A; Turcotte V; Le T; Shehata M; Schnabl S; Demirtas D; Hubmann R; Joly-Beauparlant C; Droit A; Jäger U; Staber PB; Lévesque E; Guillemette C
Br J Cancer; 2020 Jul; 123(2):240-251. PubMed ID: 32418995
[TBL] [Abstract][Full Text] [Related]
3. Function of UDP-glucuronosyltransferase 2B17 (UGT2B17) is involved in endometrial cancer.
Hirata H; Hinoda Y; Zaman MS; Chen Y; Ueno K; Majid S; Tripsas C; Rubin M; Chen LM; Dahiya R
Carcinogenesis; 2010 Sep; 31(9):1620-6. PubMed ID: 20554747
[TBL] [Abstract][Full Text] [Related]
4. UDP-glucuronosyltransferase 2B17 genotype and the risk of lung cancer among Austrian Caucasians.
Gruber M; Le T; Filipits M; Gsur A; Mannhalter C; Jäger U; Vanura K
Cancer Epidemiol; 2013 Oct; 37(5):625-8. PubMed ID: 23850147
[TBL] [Abstract][Full Text] [Related]
5. Non-canonical transcriptional regulation of the poor prognostic factor UGT2B17 in chronic lymphocytic leukemic and normal B cells.
Rouleau M; Villeneuve L; Allain EP; McCabe-Leroux J; Tremblay S; Nguyen Van Long F; Uchil A; Joly-Beauparlant C; Droit A; Guillemette C
BMC Cancer; 2024 Apr; 24(1):410. PubMed ID: 38566115
[TBL] [Abstract][Full Text] [Related]
6. Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men.
Park J; Chen L; Ratnashinge L; Sellers TA; Tanner JP; Lee JH; Dossett N; Lang N; Kadlubar FF; Ambrosone CB; Zachariah B; Heysek RV; Patterson S; Pow-Sang J
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1473-8. PubMed ID: 16896035
[TBL] [Abstract][Full Text] [Related]
7. UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?
Bhoi S; Baliakas P; Cortese D; Mattsson M; Engvall M; Smedby KE; Juliusson G; Sutton LA; Mansouri L
Haematologica; 2016 Feb; 101(2):e63-5. PubMed ID: 26589911
[No Abstract] [Full Text] [Related]
8. Exemestane and Its Active Metabolite 17-Hydroexemestane Induce UDP-Glucuronosyltransferase (UGT) 2B17 Expression in Breast Cancer Cells.
Chanawong A; Mackenzie PI; McKinnon RA; Hu DG; Meech R
J Pharmacol Exp Ther; 2017 Jun; 361(3):482-491. PubMed ID: 28404691
[TBL] [Abstract][Full Text] [Related]
9. UGT2B17 as a disease accelerator in CLL.
Zhong Y; Byrd JC
Blood; 2013 Feb; 121(7):1067-8. PubMed ID: 23411731
[No Abstract] [Full Text] [Related]
10. A Non-Canonical Role for the Glycosyltransferase Enzyme UGT2B17 as a Novel Constituent of the B Cell Receptor Signalosome.
Wagner A; Rouleau M; Villeneuve L; Le T; Peltier C; Allain ÉP; Beaudoin C; Tremblay S; Courtier F; Nguyen Van Long F; Laverdière I; Lévesque É; Banerji V; Vanura K; Guillemette C
Cells; 2023 May; 12(9):. PubMed ID: 37174695
[TBL] [Abstract][Full Text] [Related]
11. Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer.
Wong NS; Seah EZh; Wang LZ; Yeo WL; Yap HL; Chuah B; Lim YW; Ang PC; Tai BC; Lim R; Goh BC; Lee SC
Pharmacogenet Genomics; 2011 Nov; 21(11):760-8. PubMed ID: 21849928
[TBL] [Abstract][Full Text] [Related]
12. Effect of UGT2B17 deletion polymorphism on prognosis in pediatric cancer.
Ishimaru S; Yuza Y; Kaneko T; Urashima M
Pediatr Int; 2017 Apr; 59(4):427-431. PubMed ID: 27805301
[TBL] [Abstract][Full Text] [Related]
13. Genetic aspects of epitestosterone formation and androgen disposition: influence of polymorphisms in CYP17 and UGT2B enzymes.
Schulze JJ; Lorentzon M; Ohlsson C; Lundmark J; Roh HK; Rane A; Ekström L
Pharmacogenet Genomics; 2008 Jun; 18(6):477-85. PubMed ID: 18496127
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of UDP-glucuronosyltransferase 2B17 (UGT2B17) and dihydrofolate reductase (DHFR) genes deletion and the expression level of NGX6 mRNA in breast cancer.
Eskandari-Nasab E; Hashemi M; Rezaei H; Fazaeli A; Mashhadi MA; Moghaddam SS; Arbabi F; Jahantigh M; Taheri M
Mol Biol Rep; 2012 Dec; 39(12):10531-9. PubMed ID: 23053953
[TBL] [Abstract][Full Text] [Related]
15. A novel polymorphism in a forkhead box A1 (FOXA1) binding site of the human UDP glucuronosyltransferase 2B17 gene modulates promoter activity and is associated with altered levels of circulating androstane-3α,17β-diol glucuronide.
Hu DG; Gardner-Stephen D; Severi G; Gregory PA; Treloar J; Giles GG; English DR; Hopper JL; Tilley WD; Mackenzie PI
Mol Pharmacol; 2010 Oct; 78(4):714-22. PubMed ID: 20628005
[TBL] [Abstract][Full Text] [Related]
16. Impaired up-regulation of polo-like kinase 2 in B-cell chronic lymphocytic leukaemia lymphocytes resistant to fludarabine and 2-chlorodeoxyadenosine: a potential marker of defective damage response.
de Viron E; Knoops L; Connerotte T; Smal C; Michaux L; Saussoy P; Vannuffel P; Beert E; Vekemans MC; Hermans C; Bontemps F; Van Den Neste E
Br J Haematol; 2009 Dec; 147(5):641-52. PubMed ID: 19764992
[TBL] [Abstract][Full Text] [Related]
17. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.
Rossi D; Fangazio M; Rasi S; Vaisitti T; Monti S; Cresta S; Chiaretti S; Del Giudice I; Fabbri G; Bruscaggin A; Spina V; Deambrogi C; Marinelli M; Famà R; Greco M; Daniele G; Forconi F; Gattei V; Bertoni F; Deaglio S; Pasqualucci L; Guarini A; Dalla-Favera R; Foà R; Gaidano G
Blood; 2012 Mar; 119(12):2854-62. PubMed ID: 22308293
[TBL] [Abstract][Full Text] [Related]
18. UGT2B17 minor histocompatibility mismatch and clinical outcome after HLA-identical sibling donor stem cell transplantation.
Santos N; Rodríguez-Romanos R; Nieto JB; Buño I; Vallejo C; Jiménez-Velasco A; Brunet S; Buces E; López-Jiménez J; González M; Ferrá C; Sampol A; de la Cámara R; Martínez C; Gallardo D;
Bone Marrow Transplant; 2016 Jan; 51(1):79-82. PubMed ID: 26367234
[TBL] [Abstract][Full Text] [Related]
19. Gene expression of INPP5F as an independent prognostic marker in fludarabine-based therapy of chronic lymphocytic leukemia.
Palermo G; Maisel D; Barrett M; Smith H; Duchateau-Nguyen G; Nguyen T; Yeh RF; Dufour A; Robak T; Dornan D; Weisser M;
Blood Cancer J; 2015 Oct; 5(10):e353. PubMed ID: 26430724
[TBL] [Abstract][Full Text] [Related]
20. mRNA overexpression of kallikrein-related peptidase 14 (KLK14) is an independent predictor of poor overall survival in chronic lymphocytic leukemia patients.
Kontos CK; Adamopoulos PG; Papageorgiou SG; Pappa V; Scorilas A
Clin Chem Lab Med; 2016 Feb; 54(2):315-24. PubMed ID: 26351937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
